DRUG TRANSPORT IN THE LIVER - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 404

219. Shimizu M, Uno T, Sugawara K, Tateishi T. 2006. Effects of itraconazole and diltiazem
on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin
Pharmacol 61(5):538-544.
220. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. 2005. Identification of
OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther
4(8).
221. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sak-
thisekaran D, Endou H. 2002. Human organic anion transporters mediate the transport
of tetracycline. Jpn J Pharmacol 88(1):69-76.
222. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha
SH, Sekine T, Endou H. 2002. Human organic anion transporters and human organic
cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 300(3):918-
924.
223. van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ.
2001. Comparison of “type I” and “type II” organic cation transport by organic
cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther
298(1):110-115.
224. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E. 1999. Selective substrates
for non-neuronal monoamine transporters. Mol Pharmacol 56(1):1-10.
225. Thomas J, Wang L, Clark RE, Pirmohamed M. 2004. Active transport of imatinib into
and out of cells: implications for drug resistance. Blood 104(12):3739-3745.
226. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. 2005. Metformin
is a superior substrate for renal organic cation transporter OCT2 rather than hepatic
OCT1. Drug Metab Pharmacokinet 20(5):379-386.
227. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester
S, Baumann C, Lang F, Busch AE, Koepsell H. 1997. Cloning and characterization
of two human polyspecific organic cation transporters. DNA Cell Biol 16(7):871-
881.
228. Zhang L, Gorset W, Dresser MJ, Giacomini KM. 1999. The interaction of n -
tetraalkylammonium compounds with a human organic cation transporter, hOCT1. J
Pharmacol Exp Ther 288(3):1192-1198.
229. Grundemann D, Schechinger B, Rappold GA, Schomig E. 1998. Molecular identification
of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci
1(5):349-351.
230. Hayer-Zillgen M, Bruss M, Bonisch H. 2002. Expression and pharmacological profile
of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol
136(6):829-836.
231. Grundemann D, Hahne C, Berkels R, Schomig E. 2003. Agmatine is efficiently trans-
ported by non-neuronal monoamine transporters extraneuronal monoamine transporter
(EMT) and organic cation transporter 2 (OCT2). J Pharmacol Exp Ther 304(2):810-817.
232. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH,
Ganapathy V. 2000. Structure, function, and regional distribution of the organic cation
transporter OCT3 in the kidney. Am J Physiol Renal Physiol 279(3):F449-F458.
233. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. 1994.
Pharmacological characterization of multidrug resistant MRP-transfected human tumor
cells. Cancer Res 54(22):5902-5910.